Your browser is no longer supported. Please, upgrade your browser.
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E42.96 EPS (ttm)1.89 Insider Own0.10% Shs Outstand2.53B Perf Week3.60%
Market Cap205.42B Forward P/E11.99 EPS next Y6.77 Insider Trans-0.76% Shs Float2.53B Perf Month11.09%
Income4.80B PEG3.37 EPS next Q1.54 Inst Own75.00% Short Float0.89% Perf Quarter5.06%
Sales47.09B P/S4.36 EPS this Y-28.00% Inst Trans0.21% Short Ratio1.69 Perf Half Y9.77%
Book/sh13.14 P/B6.18 EPS next Y17.67% ROA6.10% Target Price93.21 Perf Year7.44%
Cash/sh- P/C- EPS next 5Y12.74% ROE19.40% 52W Range68.38 - 84.56 Perf YTD4.04%
Dividend2.60 P/FCF- EPS past 5Y12.20% ROI10.80% 52W High-4.03% Beta0.41
Dividend %3.20% Quick Ratio1.10 Sales past 5Y4.00% Gross Margin68.30% 52W Low18.67% ATR1.66
Employees74000 Current Ratio1.30 Sales Q/Q4.90% Oper. Margin10.60% RSI (14)61.94 Volatility1.67% 1.96%
OptionableYes Debt/Eq0.80 EPS Q/Q-59.70% Profit Margin11.80% Rel Volume0.56 Prev Close81.17
ShortableYes LT Debt/Eq0.72 EarningsOct 28 BMO Payout116.30% Avg Volume13.37M Price81.15
Recom2.00 SMA203.12% SMA505.75% SMA2008.07% Volume7,492,624 Change-0.02%
Sep-07-21Downgrade Morgan Stanley Overweight → Equal-Weight $85
Jul-27-21Resumed Truist Buy $92
May-20-21Downgrade Argus Buy → Hold
Apr-07-21Resumed RBC Capital Mkts Sector Perform $79
Nov-10-20Resumed Bernstein Outperform $95
Sep-29-20Initiated Berenberg Hold $88
Aug-03-20Upgrade Goldman Neutral → Buy $91 → $105
Jun-12-20Downgrade Wolfe Research Outperform → Peer Perform
Feb-27-20Initiated Barclays Overweight $93
Jan-07-20Initiated RBC Capital Mkts Sector Perform $99
Oct-17-19Resumed BofA/Merrill Neutral $90
Aug-16-19Initiated SVB Leerink Outperform
Jul-03-19Initiated Mizuho Buy $97
May-28-19Initiated Goldman Neutral
May-13-19Upgrade Atlantic Equities Neutral → Overweight
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Oct-23-21 11:00AM  
10:26AM  
Oct-22-21 03:01PM  
12:43PM  
10:08AM  
07:36AM  
06:45AM  
06:31AM  
Oct-21-21 04:03PM  
03:02PM  
01:10PM  
10:00AM  
07:23AM  
07:13AM  
12:00AM  
Oct-20-21 07:07PM  
05:45PM  
02:39PM  
11:10AM  
09:21AM  
09:02AM  
08:47AM  
08:46AM  
06:26AM  
02:18AM  
Oct-19-21 07:30PM  
03:35PM  
09:38AM  
08:58AM  
04:42AM  
04:28AM  
Oct-18-21 07:30PM  
04:16PM  
10:45AM  
07:30AM  
Oct-17-21 09:35AM  
Oct-16-21 06:10AM  
06:04AM  
Oct-15-21 04:10PM  
02:42PM  
02:14PM  
09:15AM  
07:42AM  
07:20AM  
07:15AM  
Oct-14-21 05:45PM  
02:37PM  
01:49PM  
12:57PM  
Oct-13-21 04:09PM  
04:02PM  
02:45PM  
02:32PM  
08:51AM  
Oct-12-21 02:30PM  
10:39AM  
10:07AM  
06:45AM  
06:00AM  
05:18AM  
02:39AM  
Oct-11-21 06:14PM  
09:41AM  
09:06AM  
06:34AM  
06:23AM  
06:12AM  
06:00AM  
06:00AM  
02:52AM  
Oct-10-21 05:52AM  
Oct-09-21 11:15AM  
10:23AM  
07:30AM  
06:00AM  
Oct-08-21 02:32PM  
02:14PM  
08:30AM  
06:05AM  
04:48AM  
04:20AM  
04:00AM  
Oct-07-21 09:33PM  
05:45PM  
01:48PM  
05:15AM  
05:00AM  
Oct-06-21 03:34PM  
02:32PM  
08:32AM  
07:14AM  
07:10AM  
06:40AM  
06:30AM  
05:52AM  
Oct-05-21 06:03PM  
10:20AM  
10:00AM  
09:42AM  
09:17AM  
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Clyburn FrankEVP & Pres ? Human HealthMay 10Option Exercise0.0019,3240113,672May 11 02:41 PM
Clyburn FrankEVP & Pres ? Human HealthMay 10Sale78.3219,3241,513,44094,348May 11 02:41 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 04Option Exercise75.9841731,6845,662May 06 05:04 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 04Option Exercise75.981,21292,08836,215May 06 05:02 PM
Litchfield CarolineEVP & CFOMay 04Option Exercise75.981,03978,94320,230May 06 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 04Option Exercise75.9869452,7302,612May 06 04:48 PM
Clyburn FrankEVP, Chief Commercial OfficerMay 04Option Exercise75.981,906144,81895,287May 06 04:40 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 03Option Exercise74.5087565,18835,303May 04 04:50 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 03Option Exercise74.5041230,6945,387May 04 04:55 PM
Li Dean YExecutive VP & President, MRLMay 03Option Exercise74.5075055,87512,111May 04 04:57 PM
Litchfield CarolineEVP & CFOMay 03Option Exercise74.5075055,87519,544May 04 05:01 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 03Option Exercise74.5043732,5562,068May 04 05:04 PM
LeCointe-Cephas LisaSVP Chief Ethics & Com OfficerMay 01Option Exercise74.5062246,3391,841May 04 05:04 PM
Litchfield CarolineEVP & CFOMay 01Option Exercise74.5084062,58019,082May 04 05:01 PM
Li Dean YExecutive VP & President, MRLMay 01Option Exercise74.501,03076,73511,715May 04 04:57 PM
Williams David MichaelEVP,Chief Info&Digital OfficerMay 01Option Exercise74.5056041,7205,167May 04 04:55 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise74.5090167,12434,737May 04 04:50 PM
FRAZIER KENNETH CChairman, President & CEONov 09Sale81.42280,00022,797,011411,546Nov 12 04:45 PM
Nally MichaelEVP, Chief Marketing OfficerOct 30Option Exercise75.892,287173,56013,403Nov 03 04:48 PM
MIZELL STEVENEVP, Chief HR OfficerOct 30Option Exercise75.894,574347,1217,624Nov 03 04:44 PM
Clyburn FrankEVP, Chief Commercial OfficerOct 30Option Exercise75.892,287173,56083,656Nov 03 04:55 PM